Testing a new vaccine for hookworm infection
Official title: Planning for Na-GST-1 Hookworm Vaccine Phase 2 CHIM Efficacy Trial
Funded at George Washington University · NIH-11088462 · Data updated 2026-11-12
This study is testing a new vaccine for hookworm called Na-GST-1 to see how well it protects healthy volunteers from getting infected after being exposed to hookworm larvae, and it aims to help improve health issues like iron deficiency anemia.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project start | June 5, 2025 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $242,058 |
| NIH project number | 1R34AI189333-01 |
| Project ID | NIH-11088462 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are healthy adults who have never been infected with hookworms.
✕Less likely to help
Patients who are already infected with hookworms or have a history of severe allergic reactions to vaccine components may not benefit from this research.
What this research studies
This research aims to plan a clinical trial to evaluate the effectiveness of a new hookworm vaccine called Na-GST-1. The trial will involve healthy volunteers who will receive the vaccine and then be intentionally exposed to hookworm larvae to assess the vaccine's protective effects. The study will utilize a controlled human infection model, which allows researchers to closely monitor the vaccine's impact on hookworm infection and its associated health issues, such as iron deficiency anemia. The vaccine has shown promise in earlier trials, indicating it may be safe and effective.
Why it matters
Potential benefit: If successful, this research could lead to an effective vaccine that significantly reduces the incidence of hookworm infections and their health complications.
How similar studies have gone: Previous studies have shown promising results with similar vaccine approaches, indicating potential for success in this trial.
Where this research is happening
-
George Washington University
Washington, United States Active
Researchers
- Principal investigator: Diemert, David Joseph — George Washington University
- Study coordinator: Diemert, David Joseph
Related research
Other NIH-funded projects on the same topics.
-
HLA-F and KIR3DS1: unlocking NK cell help to control HIV
A short, patient-friendly look at how a specific immune interaction might help the body control HIV and reduce long-term health problems.
-
Emerging therapies for rare maternal mitochondrial diseases with shared causes
A basket clinical trial will test new drug candidates for two ultra-rare mitochondrial diseases (MELAS and LHON-Plus) that share the same underlying energy-making problem in people who could be affected.
-
Anti-cancer vaccine for liver fluke infection and bile duct cancer
A vaccine approach aims to stop liver fluke interactions with the human bile ducts to prevent bile duct cancer in regions where the parasite is common.
-
Anti-cancer vaccine targeting the host-parasite interface during liver fluke infection
A vaccine approach aims to block how a liver fluke parasite communicates with the human liver to prevent bile duct cancer in people in Southeast Asia.
-
Understanding why youth develop type 2 diabetes and how to prevent it
A nationwide study aims to unravel why some teens with obesity develop type 2 diabetes while others don’t, and to identify factors that could help prevent it.
-
Ultrasensitive antibody-detection method to screen HIV-bNAbs
A new, ultra-sensitive test will help identify which broadly neutralizing antibodies can best block HIV-1 in people, by quickly checking how well these antibodies interact with the virus in patient-derived samples.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.